On July 19, CDC’s Advisory Committee on Immunization Practices (ACIP) recommended the use of Novavax’s COVID-19 vaccine for adult patients (ages 18 and older) for primary series vaccination. See the CDC statement. This recommendation is in line with the FDA’s Emergency Use Authorization of the vaccine for this age group. A limited supply of Novavax is available for Health Center COVID-19 Vaccine Program participants. Ordering through PA-SIIS opened on Monday, July 25. Health centers can submit a one-time order of one package (100 doses) per health center site. See these CDC resources for more information:
· Novavax COVID-19 Vaccination Operational Planning Guide
· Use of COVID-19 Vaccines in the U.S.
· Novavax COVID-19, Adjuvanted Vaccine: Overview and Safety | CDC Novavax HCP Fact Sheet 07132022 (fda.gov)
For more information, please contact Erin Babe, PACHC Public Health Program Specialist.